As a leading platform in China for innovation and integration of resources of the health industry, BPG provides optimized solutions for all segments of the massive health industrial chain through its Global Brand Ecosystem, Intelligent Application Ecosystem, Medical Service Ecosystem and Investment Ecosystem. In the recent two years, particularly, BAHEAL PHARMA has established a Health Industrial Park of over 1,000 Mu to push forward conversion of old to new kinetic energies; with AI as the poin

On January 9 - 14, the 2nd session of the 16th Qingdao People's Congress was held in the People's Hall of Qingdao. Shouldering the trust of the Qingdao people, the deputies to the Qingdao People's Congress from all walks of life in Qingdao attended the meeting to fulfill the sacred duties conferred by the Constitution and laws. As a deputy to the Qingdao People's Congress, President Fu Gang of the BAHEAL Pharmaceutical Group, centering on the spirit of the government work report, spoke glowingly

Qingdao Baheal Pharmaceutical Ltd. recently announced that, its advanced generics preparation technology has achieved major breakthrough, and Nida, an osmotic-controlled metformin-based diabetes medicine has been approved by FDA to come into the market, which will bring benefits to patients with type-2 diabetes, particularly, those patients accompanied with obesity and hyperinsulinemia.

The Meeting for promoting and introducing the Fund for Replacing Old Growth Drivers with New Ones in Qingdao and the Venture Capital Investment Summit Forum were held in the Jinjialing Financial District of Qingdao, Shandong Province on April 20, 2018. Meng Fanli, Mayor of Qingdao and deputy secretary of the Municipal Committee of the Communist Party of China attended the event and pointed out that a RMB 300 billion fund has been set up to channel financing and social capital into key projects and fields for the replacement of old driving forces with new ones. It is part of a major project to accelerate the replacement of old driving forces with new ones in Qingdao, he said.

Boston Consulting Group (BCG), one of the four major consulting companies in the world, recently released an industry analysis report, entitled Direction for the Development of the Drug Circulation Industry in China. The report noted that the drug circulation industry in China at present reveals three most important characteristics, i.e., a great number of enterprises, relatively low concentration and a dire need for optimization of industry structure; leading players active in expanding ability for comprehensive services with professional competencies yet to be improved; and constantly emerging new business formats and business models. The report summarized alignment of the drug circulation industry to international trends, the direction for its future development in China and challenges; BAHEAL Pharmaceutical Group (BPG), as a representative of innovative companies in China’s drug circulation industry, provides up- and downstream total solutions for the entire industrial chain and fully understands the future directions of the industry.